Starling Oncology, Inc. splits its revenue into 4 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Health Care Specialty Pharmacy at $98.6 million, 61% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
587
|
161
|
147
|
142
|
137
|
120
|
104
|
100
|
100
|
| Health Care Specialty Pharmacy |
343
+65.4%
share 58.5%
|
99
+57.6%
share 61.1%
|
88
+77.6%
share 59.4%
|
81
+71.1%
share 57.4%
|
76
+57.4%
share 55.6%
|
63
share 52.2%
|
49
share 47.2%
|
48
share 47.5%
|
48
share 48.3%
|
| Fee For Service |
139
-1.0%
share 23.7%
|
31
-16.7%
share 19.1%
|
32
-9.6%
share 21.8%
|
36
+10.9%
share 25.5%
|
40
+13.4%
share 29.0%
|
37
share 30.9%
|
36
share 34.1%
|
33
share 32.6%
|
35
share 35.0%
|
| Capitated Revenue |
99
+44.3%
share 16.9%
|
28
+48.5%
share 17.3%
|
27
+53.9%
share 18.3%
|
24
+34.6%
share 16.6%
|
21
+38.9%
share 15.1%
|
19
share 15.7%
|
17
share 16.8%
|
18
share 17.5%
|
15
share 14.8%
|
| Clinical Research Trials And Other Revenue |
6
-25.0%
share 1.0%
|
4
+187.5%
share 2.4%
|
1
-60.2%
share 0.6%
|
1
-71.4%
share 0.5%
|
0
-75.6%
share 0.3%
|
1
share 1.1%
|
2
share 2.0%
|
2
share 2.5%
|
2
share 1.9%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
- Listed as
- STLN (Nasdaq), DFPH (OTC), STLNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1799191
- Former names
- Oncology Institute, Inc. (until Aug 3, 2026); DFP HEALTHCARE ACQUISITIONS CORP. (until Nov 12, 2021)
Other Services-Offices & Clinics of Doctors of Medicine companies
- Hims & Hers Health, Inc. HIMS
- Teladoc Health, Inc. TDOC
- SBC Medical Group Holdings Inc SBC
- Auna S.A. AUNA
- Airsculpt Technologies, Inc. AIRS
- LifeMD, Inc. LFMD
- Westin Acquisition Corp WSTN
- Basel Medical Group Ltd BMGL
All 12 Services-Offices & Clinics of Doctors of Medicine companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.